Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Operating Leases (2021 - 2025)

Burning Rock Biotech has reported Operating Leases over the past 5 years, most recently at $3.4 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 10.75% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, down 10.75%, while the annual FY2025 figure was $3.5 million, 51.21% down from the prior year.
  • Operating Leases for Q4 2025 was $3.4 million at Burning Rock Biotech, up from $2.0 million in the prior quarter.
  • Over five years, Operating Leases peaked at $11.2 million in Q1 2021 and troughed at $512494.5 in Q4 2023.
  • A 5-year average of $4.8 million and a median of $3.3 million in 2025 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: crashed 82.32% in 2023 and later skyrocketed 1387.14% in 2024.
  • Year by year, Operating Leases stood at $7.7 million in 2021, then plummeted by 75.3% to $1.9 million in 2022, then crashed by 73.1% to $512494.5 in 2023, then surged by 653.92% to $3.9 million in 2024, then decreased by 10.75% to $3.4 million in 2025.
  • Business Quant data shows Operating Leases for BNR at $3.4 million in Q4 2025, $2.0 million in Q3 2025, and $2.5 million in Q2 2025.